康华生物：公司在建工程转固严格按照企业会计准则及相关规定执行

Core Viewpoint - Kanghua Biotech is progressing with its vaccine production expansion project, which is expected to enhance the production capacity of its core product, the freeze-dried human rabies vaccine, following the completion of various construction and regulatory phases [1] Group 1: Project Development - The company is strictly adhering to accounting standards and regulations for the transfer of construction projects to fixed assets, based on the construction progress and readiness for use [1] - The vaccine production expansion project has completed workshop construction, equipment debugging, trial production, GMP compliance checks, and on-site drug registration inspections, and is currently in the review stage for the supplementary application of production licenses [1] Group 2: Infrastructure and R&D - The Chengdu vaccine production base's first phase and the R&D center construction are crucial components of the company's new vaccine R&D and production base in Wenjiang [1] - The implementation of these projects has established a high-standard R&D center equipped with advanced research facilities and pilot test workshops, enhancing the company's R&D capabilities and technological reserves [1] - This comprehensive layout supports the current mainstream and new vaccine R&D and industrialization platforms, laying a solid foundation for ongoing technological innovation and long-term development [1]